(ABC News) — Mylan Pharmaceuticals CEO Heather Bresch defended her company’s decision to increase the price of the EpiPen during a hearing held by the House Committee on Oversight and Government Reform this afternoon.
“Price and access exist in a balance, and we believe we have struck that balance,” Bresch said, explaining that under Mylan, access to the EpiPen product had expanded dramatically.
In his opening statement, Rep. Elijah Cummings, D-Maryland, accused Mylan of increasing the price “for no discernible reason other than to get filthy rich at the expense of our constituents,” and characterized the company’s business model as corrupt.
“After Mylan takes our punches, they will fly back to their mansions in their private jets and laugh all the way to the bank while our constituents suffer, file for bankruptcy, and watch their children get sicker, and in some cases die,” Cummings said.
Mylan has faced increased scrutiny for the price of its signature product, a portable auto-injecting device for emergency treatment of severe allergic reactions. The price of a two-pack of EpiPens has risen from approximately $100 in 2009 to around $600, according to medical literature and various pharmacies across the nation.ten or redistributed.